As part of its overall strategy to bolster its biologics manufacturing facilities, Merck & Co is to acquire the entire assets and workforce of Avecia Group’s biologics business located at Billingham, UK. Avecia is a privately owned biotechnology group providing contract development and manufacturing services in the fields of microbial-derived biopharmaceuticals and oligonucleotide medicines.